Kunming Yuanrui Pharmaceutical

Kunming Yuanrui Pharmaceutical is a Chinese pharmaceutical company specializing in the research, development, manufacturing, and commercialization of chemical drugs. Originally established in 1998 following the asset restructuring of the bankrupt state-owned Kunming Antibiotic Factory, the company was subsequently acquired by the Red Coral Pharmaceutical Group and serves as one of its primary manufacturing bases. Its product portfolio spans multiple therapeutic areas, including cardiovascular health, anti-infectives, respiratory diseases, gynecology, and erectile dysfunction, with key products such as Aobixin (candesartan cilexetil dispersible tablets), indobufen tablets, and tadalafil tablets. Kunming Yuanrui Pharmaceutical operates multiple GMP-certified production lines covering tablets, granules, sprays, suppositories, and active pharmaceutical ingredients (APIs).